Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

Planning for 2022?

Reach key healthcare practitioners in Infectious Disease, Aesthetic Surgery, Cardiology, Neuro-Oncology, Gerontology, Gastroenterology and more

Oxford University Press

- PMLiVE

Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’

Results announced at the American Heart Association Scientific Sessions this week suggest the drug dramatically cuts LDL cholesterol levels

- PMLiVE

AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising

The therapy – an mRNA-encoding vascular endothelial growth factor – looks promising for patients undergoing coronary artery bypass surgery

- PMLiVE

UK expands COVID-19 vaccine plans as winter approaches

The UK government will offer a booster dose of an mRNA COVID-19 vaccine to all adults aged 40 and a second Pfizer/BioNTech shot for 16- and 17-year-olds

- PMLiVE

US President Biden nominates Robert Califf as FDA commissioner

Biden said Califf has both the experience and expertise to lead the FDA “during a critical time in our nation’s fight” against the coronavirus pandemic

- PMLiVE

Six ways to improve diversity in clinical trials

Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...

Innovative Trials

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail approved in Europe

Ronapreve (REGEN-COV in the US) has been approved for non-hospitalised, at-risk patients and for prevention of COVID-19

- PMLiVE

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

The for-profit deals are aimed to ‘progressively transition the vaccine to modest profitability’ as COVID-19 moves from a pandemic to an endemic disease

- PMLiVE

Eisai/Biogen present more data on antibody for Alzheimer’s disease

Phase 2 data shows lecanemab offers a consistent ‘robust’ effect against Alzheimer’s disease, while the phase 3 programme will test plasma biomarkers to identify preclinical disease

- PMLiVE

Organon buys Forendo in $1bn deal

Forendo purchase bolsters Organon’s pipeline with candidates in endometriosis and polycystic ovarian syndrome

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links